Literature DB >> 19331594

Modeling HCV kinetics under therapy using PK and PD information.

Emi Shudo1, Ruy M Ribeiro, Alan S Perelson.   

Abstract

BACKGROUND: Mathematical models have proven helpful in analyzing the virological response to antiviral therapy in hepatitis C virus (HCV) infected subjects.
OBJECTIVE: To summarize the uses and limitations of different models for analyzing HCV kinetic data under pegylated IFN therapy.
METHODS: We formulate mathematical models and fit them by nonlinear least square regression to patient data to estimate model parameters. We compare the goodness of fit and parameter values estimated by different models statistically. RESULTS/
CONCLUSION: The best model for parameter estimation depends on the availability and the quality of data as well as the therapy used. We also discuss the mathematical models that will be needed to analyze HCV kinetic data from clinical trials with new antiviral drugs.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19331594      PMCID: PMC2872514          DOI: 10.1517/17425250902787616

Source DB:  PubMed          Journal:  Expert Opin Drug Metab Toxicol        ISSN: 1742-5255            Impact factor:   4.481


  55 in total

1.  Albinterferon alfa-2b dosed every two or four weeks in interferon-naïve patients with genotype 1 chronic hepatitis C.

Authors:  Stefan Zeuzem; Eric M Yoshida; Yves Benhamou; Stephen Pianko; Vincent G Bain; Daniel Shouval; Robert Flisiak; Vratislav Rehak; Mircea Grigorescu; Kelly Kaita; Patrick W Cronin; Erik Pulkstenis; G Mani Subramanian; John G McHutchison
Journal:  Hepatology       Date:  2008-08       Impact factor: 17.425

2.  Modelling hepatitis C virus kinetics during treatment with pegylated interferon alpha-2b: errors in the estimation of viral kinetic parameters.

Authors:  E Shudo; R M Ribeiro; A S Perelson
Journal:  J Viral Hepat       Date:  2008-05       Impact factor: 3.728

3.  A hepatitis C viral kinetic model that allows for time-varying drug effectiveness.

Authors:  Emi Shudo; Ruy M Ribeiro; Andrew H Talal; Alan S Perelson
Journal:  Antivir Ther       Date:  2008

4.  Influence of extrahepatic viral infection on the natural history of hepatitis C.

Authors:  María Inés Barría; Jorge Vera-Otarola; Ursula León; Valeska Vollrath; Delphine Marsac; Arnoldo Riquelme; Marcelo López-Lastra; Alejandro Soza
Journal:  Ann Hepatol       Date:  2008 Apr-Jun       Impact factor: 2.400

5.  Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response.

Authors:  Peter Ferenci; Hermann Laferl; Thomas-Matthias Scherzer; Michael Gschwantler; Andreas Maieron; Harald Brunner; Rudolf Stauber; Martin Bischof; Bernhard Bauer; Christian Datz; Karin Löschenberger; Elisabeth Formann; Katharina Staufer; Petra Steindl-Munda
Journal:  Gastroenterology       Date:  2008-05-27       Impact factor: 22.682

Review 6.  Dynamic evolution of therapy for chronic hepatitis C: how will novel agents be incorporated into the standard of care?

Authors:  Stefan Zeuzem; David R Nelson; Patrick Marcellin
Journal:  Antivir Ther       Date:  2008

Review 7.  Treatment predictors of a sustained virologic response in hepatitis B and C.

Authors:  Annika Kau; Johannes Vermehren; Christoph Sarrazin
Journal:  J Hepatol       Date:  2008-07-31       Impact factor: 25.083

8.  Modeling complex decay profiles of hepatitis B virus during antiviral therapy.

Authors:  Harel Dahari; Emi Shudo; Ruy M Ribeiro; Alan S Perelson
Journal:  Hepatology       Date:  2009-01       Impact factor: 17.425

9.  Antiviral suppression vs restoration of RIG-I signaling by hepatitis C protease and polymerase inhibitors.

Authors:  Yuqiong Liang; Hisashi Ishida; Oliver Lenz; Tse-I Lin; Origène Nyanguile; Kenny Simmen; Richard B Pyles; Nigel Bourne; Minkyung Yi; Kui Li; Stanley M Lemon
Journal:  Gastroenterology       Date:  2008-07-22       Impact factor: 22.682

10.  Mathematical modeling of HCV infection and treatment.

Authors:  Harel Dahari; Emi Shudo; Ruy M Ribeiro; Alan S Perelson
Journal:  Methods Mol Biol       Date:  2009
View more
  17 in total

Review 1.  Modelling hepatitis C therapy--predicting effects of treatment.

Authors:  Alan S Perelson; Jeremie Guedj
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-06-30       Impact factor: 46.802

2.  Twice-weekly pegylated interferon-α-2a and ribavirin results in superior viral kinetics in HIV/hepatitis C virus co-infected patients compared to standard therapy.

Authors:  Alison A Murphy; Eva Herrmann; Anu O Osinusi; Lynn Wu; William Sachau; Richard A Lempicki; Jun Yang; Tje L Chung; Tei L Chung; Brad J Wood; Bart L Haagmans; Shyam Kottilil; Michael A Polis
Journal:  AIDS       Date:  2011-06-01       Impact factor: 4.177

Review 3.  Viral kinetic modeling: state of the art.

Authors:  Laetitia Canini; Alan S Perelson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2014-06-25       Impact factor: 2.745

4.  Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial.

Authors:  Anuoluwapo Osinusi; Eric G Meissner; Yu-Jin Lee; Dimitra Bon; Laura Heytens; Amy Nelson; Michael Sneller; Anita Kohli; Lisa Barrett; Michael Proschan; Eva Herrmann; Bhavana Shivakumar; Wenjuan Gu; Richard Kwan; Geb Teferi; Rohit Talwani; Rachel Silk; Colleen Kotb; Susan Wroblewski; Dawn Fishbein; Robin Dewar; Helene Highbarger; Xiao Zhang; David Kleiner; Brad J Wood; Jose Chavez; William T Symonds; Mani Subramanian; John McHutchison; Michael A Polis; Anthony S Fauci; Henry Masur; Shyamasundaran Kottilil
Journal:  JAMA       Date:  2013-08-28       Impact factor: 56.272

5.  Dysregulation of innate immunity in hepatitis C virus genotype 1 IL28B-unfavorable genotype patients: impaired viral kinetics and therapeutic response.

Authors:  Susanna Naggie; Anu Osinusi; Antonios Katsounas; Richard Lempicki; Eva Herrmann; Alexander J Thompson; Paul J Clark; Keyur Patel; Andrew J Muir; John G McHutchison; Joerg F Schlaak; Martin Trippler; Bhavana Shivakumar; Henry Masur; Michael A Polis; Shyam Kottilil
Journal:  Hepatology       Date:  2012-07-02       Impact factor: 17.425

6.  Severity of liver disease affects HCV kinetics in patients treated with intravenous silibinin monotherapy.

Authors:  Laetitia Canini; Swati DebRoy; Zoe Mariño; Jessica M Conway; Gonzalo Crespo; Miquel Navasa; Massimo D'Amato; Peter Ferenci; Scott J Cotler; Xavier Forns; Alan S Perelson; Harel Dahari
Journal:  Antivir Ther       Date:  2014-06-10

Review 7.  Hepatitis C viral kinetics: the past, present, and future.

Authors:  Anushree Chatterjee; Patrick F Smith; Alan S Perelson
Journal:  Clin Liver Dis       Date:  2013-02       Impact factor: 6.126

8.  Pegylated interferon fractal pharmacokinetics: individualized dosing for hepatitis C virus infection.

Authors:  Mamta K Jain; Jotam G Pasipanodya; Lara Alder; William M Lee; Tawanda Gumbo
Journal:  Antimicrob Agents Chemother       Date:  2012-11-26       Impact factor: 5.191

Review 9.  Mathematical modelling of HCV infection: what can it teach us in the era of direct-acting antiviral agents?

Authors:  Anushree Chatterjee; Jeremie Guedj; Alan S Perelson
Journal:  Antivir Ther       Date:  2012-10-05

10.  Modelling the interaction between danoprevir and mericitabine in the treatment of chronic HCV infection.

Authors:  Laetitia Canini; Jeremie Guedj; Anushree Chatterjee; Annabelle Lemenuel-Diot; Patrick F Smith; Alan S Perelson
Journal:  Antivir Ther       Date:  2015-11-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.